Advertisement

Staging of Malignant Pleural Mesothelioma

  • Patricia M. de Groot
  • Girish S. Shroff
  • Carol C. Wu
  • David R. Rice
  • Brett W. Carter
Chapter

Abstract

Primary malignancy of the pleura is rare and usually has a poor prognosis. Malignant pleural mesothelioma is linked to occupational and environmental exposures with a latency period of 2–6 decades. Patients usually present late in the course of the disease with chest pain, dyspnea, and weight loss. Outcomes are related to both the histological subtype of the tumor and staging at presentation. Computed tomography (CT) is the imaging modality most commonly used for preliminary noninvasive clinical staging. Magnetic resonance (MR) imaging, particularly dynamic sequences, is useful in evaluating chest wall, diaphragm, and mediastinal invasion. It can be helpful when CT findings are equivocal to distinguish resectable from unresectable disease. Positron-emission tomography (PET)/CT is performed in patients being considered for surgical resection, as it may identify nodal and/or distant metastases not seen on CT. PET/CT may also have a role in evaluation of response to treatment and detection of recurrent disease. The 8th edition of the TNM staging system is in effect as of January 1, 2018.

Keywords

Malignant pleural mesothelioma Epithelioid mesothelioma Sarcomatoid mesothelioma Staging 

References

  1. 1.
    Mark EJ, Kradin RL. Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor. Semin Diagn Pathol. 2006;23(1):25–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesotheliomas and asbestos exposure in Northwestern Cape Province. Br J Ind Med. 1960;17:260–71.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med. 1965;22(4):261–9.PubMedPubMedCentralGoogle Scholar
  4. 4.
    IARC. Monographs on evaluation of carcinogenic risk to humans: World Health Organization Press; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php. Accessed 28 July 2017Google Scholar
  5. 5.
    Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: an update. Clin Respir J. 2014;8(1):1–10.CrossRefPubMedGoogle Scholar
  6. 6.
    Carbone M, Baris YI, Bertino P, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A. 2011;108(33):13618–23.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6.PubMedPubMedCentralGoogle Scholar
  8. 8.
    World Health Organization. Asbestos: elimination of asbestos-related diseases: World Health Organization Media Centre; 2017. http://www.who.int/mediacentre/factsheets/fs343/en/. Accessed 06 Sept 2017Google Scholar
  9. 9.
    Schuz J, Schonfeld SJ, Kromhout H, et al. A retrospective cohort study of cancer mortality in employees of a Russian chrysotile asbestos mine and mills: study rationale and key features. Cancer Epidemiol. 2013;37(4):440–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Nickell LT Jr, Lichtenberger JP 3rd, Khorashadi L, Abbott GF, Carter BW. Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014;34(6):1692–706.CrossRefPubMedGoogle Scholar
  11. 11.
    Galateau-Salle F, Churg A, Roggli V, Travis WD. The 2015 World Health Organization classification of tumors of the Pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11(2):142–54.CrossRefPubMedGoogle Scholar
  12. 12.
    NCCN. Malignant pleural mesothelioma NCCN Evidence Blocks. NCCN.org: NCCN; 2017.Google Scholar
  13. 13.
    Agarwal PP, Seely JM, Matzinger FR, et al. Pleural mesothelioma: sensitivity and incidence of needle track seeding after image-guided biopsy versus surgical biopsy. Radiology. 2006;241(2):589–94.CrossRefPubMedGoogle Scholar
  14. 14.
    Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754–8.CrossRefPubMedGoogle Scholar
  15. 15.
    West SD, Foord T, Davies RJ. Needle-track metastases and prophylactic radiotherapy for mesothelioma. Respir Med. 2006;100(6):1037–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Pass H, Giroux D, Kennedy C, et al. The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation. J Thorac Oncol. 2016;11(12):2082–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Nowak AK, Chansky K, Rice DC, et al. The IASLC Mesothelioma Staging Project: Proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089–99.CrossRefPubMedGoogle Scholar
  18. 18.
    Rusch VW, Chansky K, Kindler HL, et al. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016;11(12):2112–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Rice D, Chansky K, Nowak A, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2100–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol. 1990;154(3):487–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105–19.CrossRefPubMedGoogle Scholar
  22. 22.
    Sharma A, Fidias P, Hayman LA, Loomis SL, Taber KH, Aquino SL. Patterns of lymphadenopathy in thoracic malignancies. Radiographics. 2004;24(2):419–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Kim SB, Varkey B, Choi H. Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy. Chest. 1987;91(2):279–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999;172(4):1039–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Gill RR, Umeoka S, Mamata H, et al. Diffusion-weighted MRI of malignant pleural mesothelioma: prelimiary assessment of apparent diffusion coefficient in histologic subtypes. AJR Am J Roentgenol. 2010;19592:W125–30.CrossRefGoogle Scholar
  26. 26.
    Rusch VW. Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach. Ann Cardiothorac Surg. 2012;1(4):523–31.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Patricia M. de Groot
    • 1
  • Girish S. Shroff
    • 1
  • Carol C. Wu
    • 1
  • David R. Rice
    • 2
  • Brett W. Carter
    • 1
  1. 1.Department of Diagnostic RadiologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Thoracic and Cardiovascular SurgeryThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations